Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of enterobacteriaceae and nonfermentative gram-negative bacilli

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2849-2857

  Mendes, Rodrigo E ^a   Alley, M R K ^b   Sader, Helio S ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; GENTAMICIN; GSK 2251052; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CITROBACTER FREUNDII; DRUG POTENCY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GENOTYPE; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; BORON; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN SYNTHESIS INHIBITORS;

EID: 84877869830     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00160-13     Document Type: Article

References (40)

1. Infectious Diseases Society of America, Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: Policy recommendations to save lives. Clin. Infect. Dis. 52:S397-S428.
2. Gould IM. 2011. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 66(Suppl 4):iv17-iv21.
3. Rahal JJ. 2009. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin. Infect. Dis. 49(Suppl 1):S4-S10.
4. Livermore DM. 2009. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64(Suppl. 1):i29-i36.
5. Livermore DM, Woodford N. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413-420.
6. Livermore DM. 2011. Discovery research: The scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66:1941-1944.
7. Livermore DM. 2007. Introduction: The challenge of multiresistance. Int. J. Antimicrob. Agents 29(Suppl 3):S1-S7.
8. Rossolini GM, Mantengoli E, Docquier JD, Musmanno RA, Coratza G. 2007. Epidemiology of infections caused by multiresistant gramnegatives: ESBLs, MBLs, panresistant strains. New Microbiol. 30:332-339.
9. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34:634-640.
10. Poirel L, Pitout JD, Nordmann P. 2007. Carbapenemases: Molecular diversity and clinical consequences. Future Microbiol. 2:501-512.
11. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol. 19:588-595.
12. Nordmann P, Poirel L. 2002. Emerging carbapenemases in Gramnegative aerobes. Clin. Microbiol. Infect. 8:321-331.
13. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. 2009. Carbapenem resistance among Pseudomonas aeruginosa strains from India: Evidence for nationwide endemicity of multiple metallo-β-lactamase clones (VIM-2,-5,-6, and-11 and the newly characterized VIM-18). Antimicrob. Agents Chemother. 53:1225-1227.
14. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. 2011. Early dissemination of NDM-1-and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY antimicrobial surveillance program, 2006-2007. Antimicrob. Agents Chemother. 55:1274-1278.
15. Doi Y, Arakawa Y. 2007. 16S ribosomal RNA methylation: Emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45: 88-94.
16. Baker SJ, Tomsho JW, Benkovic SJ. 2011. Boron-containing inhibitors of synthetases. Chem. Soc. Rev. 40:4279-4285.
17. Hernandez V, Crepin T, Palencia A, Cusack S, Akama T, Baker SJ, Bu W, Feng L, Freund YR, Liu L, Meewan M, Mohan M, Mao W, Rock FL, Sexton H, Sheoran A, Zhang Y, Zhang YK, Zhou Y, Nieman JA, Anugula MR, Keramane EM, Savariraj K, Reddy DS, Sharma R, Subedi R, Singh R, O'Leary A, Simon NL, De Marsh PL, Mushtaq S, Warner M, Livermore DM, Alley MR, Plattner JJ. 2013. Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria. Antimicrob. Agents Chemother. 57:1394-1403.
18. Cormican MG, Marshall SA, Jones RN. 1996. Detection of extendedspectrum β-lactamase (ESBL)-producing strains by the Etest ESBL screen. J. Clin. Microbiol. 34:1880-1884.
19. Castanheira M, Mendes RE, Rhomberg PR, Jones RN. 2008. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: Molecular evaluation from the MYSTIC program (2007). Microb. Drug Resist. 14:211-216.
20. Castanheira M, Mendes RE, Woosley LN, Jones RN. 2011. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: Report from the SENTRY antimicrobial surveillance programme (2007-09). J. Antimicrob. Chemother. 66:1409-1411.
21. Castanheira M, Sader HS, Jones RN. 2010. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug Resist. 16:61-65.
22. Le J, Castanheira M, Burgess DS, McKee B, Iqbal R, Jones RN. 2010. Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California. J. Clin. Microbiol. 48:623-625.
23. Mendes RE, Bell JM, Turnidge JD, Yang Q, Yu Y, Sun Z, Jones RN. 2008. Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene. Antimicrob. Agents Chemother. 52:798-799.
24. Castanheira M, Bell JM, Turnidge JD, Mendes RE, Jones RN. 2010. Dissemination and genetic context analysis of blaVIM-6 among Pseudomonas aeruginosa isolates in Asian-Pacific nations. Clin. Microbiol. Infect. 16:186-189.
25. Castanheira M, Fritsche TR, Sader HS, Jones RN. 2008. RmtD 16S RNA methylase in epidemiologically unrelated SPM-1-producing Pseudomonas aeruginosa isolates from Brazil. Antimicrob. Agents Chemother. 52:1587-1588.
26. Castanheira M, Sader HS, Jones RN, Debbia E, Picao RC, Gales AC. 2007. In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: A SENTRY antimicrobial surveillance program report. Microb. Drug Resist. 13:130-134.
27. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. 2005. Dissemination and diversity of metallo-β-lactamases in Latin America: Report from the SENTRY antimicrobial surveillance program. Int. J. Antimicrob. Agents 25:57-61.
28. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. 2004. Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother. 48: 4654-4661.
29. Mendes RE, Castanheira M, Garcia P, Guzman M, Toleman MA, Walsh TR, Jones RN. 2004. First isolation of blaVIM-2 in Latin America: Report from the SENTRY antimicrobial surveillance program. Antimicrob. Agents Chemother. 48:1433-1434.
30. Garza-Ramos U, Morfin-Otero R, Sader HS, Jones RN, Hernandez E, Rodriguez-Noriega E, Sanchez A, Carrillo B, Esparza-Ahumada S, Silva-Sanchez J. 2008. Metallo-β-lactamase gene blaIMP-15 in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. Antimicrob. Agents Chemother. 52:2943-2946.
31. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. 2009. Emergence and widespread dissemination of OXA-23,-24/40 and-58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: Report from the SENTRY surveillance program. J. Antimicrob. Chemother. 63: 55-59.
32. Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G. 2009. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin. Microbiol. Infect. 15:588-592.
33. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
34. Clinical and Laboratory Standards Institute. 2012. M100-S22. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
35. Pfizer, Inc. 2011. Tygacil package insert. Pfizer, Inc., New York, NY.
36. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H. 2010. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: Molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 50:364-373.
37. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: Therapeutic approach and infection control. Clin. Microbiol. Infect. 16:102-111.
38. Tomas M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N. 2010. Efflux pumps, OprD porin, AmpC β-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 54:2219-2224.
39. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
40. Fihman V, Le Monnier A, Corvec S, Jaureguy F, Tankovic J, Jacquier H, Carbonnelle E, Bille E, Illiaquer M, Cattoir V, Zahar Jr. 2012. Stenotrophomonas maltophilia-the most worrisome threat among unusual non-fermentative Gram-negative bacilli from hospitalized patients: A prospective multicenter study. J. Infect. 64:391-398.